ClinicalTrials.gg
TerminatedNCT05481645Updated Jan 9, 2026

Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus.

A Phase 2 interventional study of TQB2450 injection and Anlotinib Hydrochloride Capsule in Advanced Endometrial Cancer and Sarcoma of Uterus, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Terminated at 11 sites in China. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-09.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 2, Interventional, and Treatment

Why this study was terminated
Per sponsor request. Premature closure was not prompted by any safety or efficacy concerns.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
71
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 170 studies in Endometrial Neoplasms with a site in China — 98 open to participants now, 120 under way, 21 of them phase 3. Endometrial Neoplasms · China.

Enrollment
95th of 140
71 · median 115
Started
2022
with 22 others
Phase 2
41 of 170
29 open now
Registered
65th of 170
by date
Lead sponsor
4 of 170
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Among the 170 studies in Endometrial Neoplasms with a site in China, this one is the 95th largest by enrollment of the 140 interventional ones that give a count, is one of 23 that started in 2022, is one of 41 in phase 2, and was the 65th registered.

Endometrial Neoplasms

1,428 studies on the registry are indexed under Endometrial Neoplasms; 472 are open to participants now.

Browse Endometrial Neoplasms studies →

Open to participants now

98 of the 170 studies in Endometrial Neoplasms with a site in China are open now. Recruiting first, the newest first:

93 more — sign in →

All 98 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 356 Endometrial Neoplasms studies recruiting now, 266 (75%) set no upper age limit and 54 (15%) stop at 75 or younger; 26 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 170 studies in Endometrial Neoplasms with a site in China, or all of them as a file.
02

Study summary

This clinical study plans to enroll 69 endometrial cancer patients and 5-10 uterine sarcoma patients. The trial is divided into a lead-in phase and a main phase. The lead-in phase will include 9 subjects, while the main phase will enroll 60 endometrial cancer patients randomized 1:1. Additionally, 5-10 uterine sarcoma patients will be enrolled. The study aims to evaluate the efficacy and safety of TQB2450 injection combined with chemotherapy ± anlotinib hydrochloride capsules as first-line treatment, followed by TQB2450 injection monotherapy ± anlotinib hydrochloride capsules as maintenance therapy for advanced endometrial cancer or uterine sarcoma. The study will also explore efficacy-related biomarkers, mechanisms of action, safety and/or pathological mechanisms, and surgical conversion rates. The primary endpoint is ORR (Objective Response Rate).

03

Conditions studied

  • Advanced Endometrial Cancer
  • Sarcoma of Uterus
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The subjects voluntarily participated in this study, signed the , and had good compliance;
  • Age: ≥18 years old (when signing the informed consent form); PS score: 0-1; expected survival period of more than 3 months; (BMI) > 18.5 and weight > 40kg;
  • Who have not received systemic anticancer therapy and are not suitable for receiving treatment other than systemic treatment:

    1. Group 1 and 2: Stage III/IV epithelial endometrial cancer (including endometrioid carcinoma, non-endometrioid carcinoma, carcinosarcoma) confirmed by histopathology, and the subject also needs to meet one of the following categories:

      1. Newly diagnosed subjects: there are still residual lesions visible on imaging after non-radical surgery;
      2. Subjects with initial recurrence: if the subject received systemic platinum-based and/or neoadjuvant chemotherapy,and the recurrence time is more than 6 months from the end of the last chemotherapy,then the previous chemotherapy is allowed.
    2. Group 3: Stage I-IV sarcoma of uterus, and the subject also needs to meet one of the following categories:

      1. Newly diagnosed/initial recurrence subject of high grade endometrial stromal sarcoma (ESS)、undifferentiated Uterine sarcoma (UUS) , uterine Leiomyosarcoma and adenosarcoma(uLMS) with sarcoma overgrowth (OS). The definition of new diagnosis and initial recurrence is the same as above.
      2. Low grade ESS, adenosarcoma without SO and other Uterine sarcoma with ER+/PR+,the subjects who failed in antiestrogen treatment.
  • According to the 1.1 criteria, there is at least one . If the measurable lesion is located in the area of previous radiotherapy, it should be clearly defined as progressing state;
  • Tumor tissue samples can be provided to detect MSI/MMR status or traceable test reports;
  • The main organs function well and meet the following standards:

    1. Blood routine examination standards (no blood transfusion within 7 days before screening, no correction with hematopoietic stimulating factor drugs):

      1. (HGB) ≥90 g/L;
      2. The absolute value of neutrophils (NEUT)≥1.5×109/L;
      3. count (PLT) ≥ 90 × 109/L;
    2. The biochemical examination shall meet the following standards:

      1. Total (TBIL) ≤ 1.5 times the (ULN);
      2. (ALT) and aspartate aminotransferase (AST) ≤ 2.5×ULN. If accompanied by liver , ALT and AST≤5×ULN;
      3. Serum creatinine (Cr) ≤ 1.5×ULN or (Ccr) ≥ 60ml/min;
      4. Serum albumin (ALB)>30g/L;
    3. Urine routine examination standard: urine routine indicates urine protein \<++; if urine protein ≥++, it is necessary to confirm the 24-hour urine protein quantitative ≤1.0g;
    4. Coagulation function or thyroid function tests should meet the following criteria:

      1. (PT), activated partial thromboplastin time (APTT), international normalized ratio (INR) ≤ 1.5×ULN (no anticoagulation therapy);
      2. Thyroid-stimulating hormone (TSH) ≤ ULN; T3 and T4 levels should be investigated if abnormal, and normal T3 and T4 levels can be selected.
    5. Echocardiography assessment: (LVEF) ≥50%.
    6. 12-lead evaluation: \<470ms.
  • Female subjects should agree that measures (such as intrauterine devices or condoms) must be used during the study period and within 6 months after the end of the study; the serum pregnancy test must be negative within 7 days before study enrollment, and must be Non-lactating subjects.

Exclusion criteria

Exclusion Criteria:

  • Tumor disease and medical history:

    1. Other malignant tumors that have occurred or are currently concurrently present within 3 years. The following conditions were eligible for enrollment: other treated with a single surgery, achieving 5 consecutive years of disease-free survival (DFS); cured cervical carcinoma in situ, non-melanoma skin cancer, and superficial bladder tumors [Ta ( non-invasive tumor), Tis (carcinoma in situ) and T1 (tumor-infiltrating basement membrane)];
    2. Pathologically suggested endometrial leiomyosarcoma, endometrial stromal sarcoma, undifferentiated uterine sarcoma or other high-grade sarcoma (Applicable to group 1 and 2), Pathologically suggested epithelial endometrial cancer or Carcinosarcoma (Applicable to group 3);
    3. The presence of tumor thrombus, spinal cord compression caused by bone , or cancerous meningitis;
    4. Imaging (CT or MRI) shows that the tumor has invaded around important blood vessels or the investigator judges that the tumor is very likely to invade important blood vessels and cause fatal bleeding during the follow-up study;
    5. Severe bone damage caused by tumor bone metastasis; including weight-bearing bone pathological fractures and spinal cord compression that occurred within 6 months or predicted by the investigator to be likely to occur in the near future;
    6. Uncontrolled pleural effusion, pericardial effusion or ascites judged by the investigator that still needs repeated drainage.
  • Previous anti-tumor therapy or concomitant medication (the is calculated from the end of the last treatment):

    1. Previously received anti-angiogenesis drugs, related immunotherapy drugs for , PD-L1, CTLA-4;
    2. Received drugs with immunomodulatory function, chemotherapy, radiotherapy, clinical trial drug treatment, traditional Chinese medicine or proprietary Chinese medicine with anti-tumor indications, or other anti-cancer therapy within 4 weeks before receiving the study drug for the first time;
    3. Received hormone therapy for endometrial cancer within 1 week before receiving the first study drug treatment;
    4. It is not satisfied that at least 5 half-lives have elapsed from the last use of the targeted drug to the first receiving of the study drug, if it is a combination drug, the drug with the longest half-life shall be calculated;
    5. Those who have undergone major surgery, major surgical treatment, incisional , obvious traumatic injury, or have not recovered sufficiently from previous surgery in the judgment of the investigator within 3 weeks before the first treatment with the study drug, or are expected to be required during the study period. Major surgery;
    6. The toxicity related to previous anti-tumor therapy has not recovered to ≤ grade 1, except for alopecia and grade 2 peripheral neuropathy.
  • Comorbid diseases and medical history:

    1. History of liver-related diseases: a. Decompensated cirrhosis; b. Active or chronic hepatitis; c. Bleeding disease secondary to hepatic insufficiency.
    2. Kidney related medical history: a. Renal failure requiring hemodialysis or peritoneal dialysis; b. Past or existing nephrotic syndrome, chronic nephritis.
    3. Cardiovascular and cerebrovascular related medical history: a. Suffering from epilepsy and requiring treatment; b. class II-IV heart failure, second-degree or higher heart block, myocardial infarction within the past 6 months or Arterial thrombosis events, unstable arrhythmia or unstable angina; c. Cerebrovascular accident, cerebral infarction, etc. within 6 months; d. If the treatment can adequately control blood pressure, the group is allowed to enter the group; e. Past or current heart valve inflammation, endocarditis; f. Cardiovascular syncope, pathological ventricular arrhythmia.
    4. Gastrointestinal-related medical history: a. Inability to take oral medications; b. History of malabsorption syndrome or other diseases that interfere with gastrointestinal absorption; c. Active peptic ulcer or ulcerated lower gastrointestinal tract in the past 6 months Treated for inflammation; d. Persistent chronic diarrhea of grade 2 and above despite maximum medical treatment.
    5. Lung-related medical history: a. History of idiopathic pulmonary fibrosis, organized pneumonia, drug-induced pneumonia, idiopathic pneumonia, or evidence of active pneumonia found on chest CT scan during screening; b. Bronchodilator required Medically intervened bronchial asthma; c. The clinical manifestations are suspected to be tuberculosis, T-SPOT positive is judged by the investigator to have tuberculosis infection or active tuberculosis within 1 year before enrollment;
    6. Endocrine-related medical history: a. Poor control of type I or II diabetes; b. History of pituitary or adrenal dysfunction; c. Thyroid-stimulating hormone (TSH) > , if T3 and T4 levels are normal, they can be enrolled.
    7. Immune-related medical history: a. A history of immunodeficiency, including positive or other acquired and congenital immunodeficiency diseases; b. Organ transplantation planned or previously received, or hematopoietic stem cells received within 60 days before the first dose Transplant, or have obvious host transplant response; c. Active disease; d. Systemic or topical or hormonal therapy is required to achieve immunosuppression, and continue to be used within 7 days before the first dose , or patients who still need immunosuppressive drugs within 5 half-lives before the first dose.
    8. Bleeding risk: a. Suffering from bleeding (hemoptysis), coagulation disease or using warfarin, aspirin and other antiplatelet aggregation drugs (except aspirin ≤100 mg/d for prophylaxis); b. Regardless of severity, there are any signs or history of bleeding constitution; c. within 4 weeks before the first dose, any CTC AE ≥ grade 3 bleeding or bleeding events;
    9. The patient has an active systemic infection or an excessive viral load;
    10. Combining serious or not well-controlled diseases or diseases that the investigator determines may have a greater risk or affect the completion of the study, including but not limited to: a. History of clear neurological or mental disorders; b. Treponema pallidum specific antibody positive.
    11. Those who have a history of drug abuse and cannot quit or have a history of drug use.
  • Research and treatment related:

    1. History of vaccination with within 28 days before the start of study treatment, inactivated vaccine within 7 days, or planned vaccination during the study period;
    2. Those who have a history of severe allergic diseases, severe drug allergies, and are known to be allergic to macromolecular protein preparations or TQB2450 injection or any components in the prescription of Anlotinib capsules, their adjuvants and similar drugs;
  • Subjects with insufficient compliance or other reasons are not suitable for enrollment after the investigator's assessment.
Terms in these criteria, in plain language(31)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
71 participants (actual)

Study arms

  • Experimental
    Group one

    First-line treatment: TQB2450 injection 1200mg,d1/Q3W+Carboplatin Injection, AUC=5 mg/ml.min,d1/Q3W + Paclitaxel Injection 175mg/m2,d1/Q3W;6-8 cycles; Maintenance treatment: TQB2450 injection, 1200mg,d1/Q3W

    Drug: TQB2450 injection · Drug: Carboplatin Injection · Drug: Paclitaxel Injection

  • Experimental
    Group two

    First-line treatment: TQB2450 Injection 1200mg, d1/Q3W + Anlotinib Hydrochloride Capsules 8mg/qd, d8-21/Q3W + Carboplatin Injection AUC=5 mg/ml.min, d1/Q3W + Paclitaxel Injection 175mg/m2, d1/Q3W ; 6-8 cycles; Maintenance treatment: TQB2450 injection+ Anlotinib Hydrochloride Capsules 8mg/qd, d8-21/Q3W

    Drug: TQB2450 injection · Drug: Anlotinib Hydrochloride Capsule · Drug: Carboplatin Injection · Drug: Paclitaxel Injection

  • Experimental
    Group three

    First-line treatment stage: TQB2450 injection 1200mg, d1/Q3W + anlotinib hydrochloride capsules 8mg/qd, d8-21/Q3W+ chemotherapy(① Doxorubicin Hydrochloride Injection 60mg/㎡,d1/Q3W; or ② Gemcitabine Hydrochloride Injection 900mg/㎡, d1, d8/Q3W+ Docetaxel Injection 75mg/㎡, d8/Q3W); 6-8 cycles; Maintenance phase: TQB2450 injection 1200mg, d1/Q3W+ Anlotinib hydrochloride capsules 10mg/qd, d8-21/Q3W

    Drug: TQB2450 injection · Drug: Anlotinib Hydrochloride Capsule · Drug: Doxorubicin Hydrochloride Injection · Drug: Gemcitabine Hydrochloride Injection · Drug: Docetaxel injection

Interventions

  • TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents the binding of PD-L1 to PD-1 and B7.1 receptors on the surface of T cells, thereby reactivating T cells and enhancing the immune response.

  • Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor.

  • Carboplatin which s similar to alkylating agent, is a second-generation platinum anti-tumor drug, which mainly causes cross-linking of DNA within and between chains, destroys DNA molecules, and disintegrates the helix.

  • Paclitaxel is a diterpene alkaloid with anticancer activity

  • Doxorubicin hydrochloride is a cycle non-specific anticancer chemotherapy drug, which directly acts on DNA, changes the nature of DNA template, and inhibits DNA polymerase.

  • Gemcitabine is a cell cycle specific antimetabolic drug, which mainly acts on tumor cells at the DNA synthesis stage.

  • Docetaxel is an anti-tumor drug of paclitaxel, which plays an anti-tumor role by interfering with the microtubule network necessary for cell Mitosis and interphase cell function.

06

What researchers measure

Primary outcomes

  1. Investigator-assessed objective response rate (ORR)

    The proportion of patients whose tumors have shrunk to a certain amount and maintained for a certain period of time, including cases with complete remission and partial remission

    Time frame: Through study completion, an average of 24 months

Secondary outcomes

  1. Progression Free Survival (PFS)

    From randomization to the first occurrence of disease progression or death from any cause. Disease progression refers to tumor growth, or the metastasis of primary tumor lesions, or the discovery of new lesions, etc.

    Time frame: From data of randomization until the date of first documented progression or date death from any cause, whichever came first, assessed up to 24 months

  2. Overall survival (OS)

    From randomization to the time of death of death from any cause

    Time frame: From date of randomization until the date of death from any cause, assessed up to 60 months

  3. Duration of Remission (DOR)

    The period from the first judgment of complete remission (CR) or partial remission (PR) to the discovery of disease progression (PD).

    Time frame: The length of time the patient received this regimen to keep the tumor shrinking, through study completion, an average of 24 months

  4. Disease Control Rate (DCR)

    the proportion of patients whose tumors shrink or remain stable for a certain period of time, including complete remission (CR, Complete Response), partial remission (PR, Partial Response) and stable (SD, stable Disease) cases

    Time frame: Through study completion, an average of 24 months

  5. Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)

    The occurrence of all adverse events (AEs), serious adverse events (SAEs) and treatment-related adverse events (TEAEs).

    Time frame: Baseline to other antitumor therapy, through study completion, an average of 24 months

  6. Abnormal laboratory test indicators

    The incidence of abnormal laboratory test indicators of participants by attachment 1 in the test protocol.

    Time frame: Baseline to other antitumor therapy, through study completion, an average of 24 months

  7. The surgical conversion rate

    The proportion of subjects who meet the criteria and undergo radical resection surgery.

    Time frame: Baseline to other antitumor therapy, through study completion, an average of 24 months

07

Study locations

11 sites
  • Sun Yat-sen Memorial Hospital
    Guangzhou, Guangdong 510120, China
  • Zhongnan Hospital of Wuhan University
    Wuhan, Hubei 430062, China
  • Hunan Cancer Hospital
    Changsha, Hunan 410013, China
  • Taizhou People's Hospital
    Taizhou, Jiangsu 225399, China
  • Liaoning Cancer Hospital & Institute
    Shenyang, Liaoning 110801, China
  • The First Affiliated Hospital of Xi'an Jiaotong University
    Xi'an, Shaanxi 710061, China
  • Shandong Cancer Hospital
    Jinan, Shandong 250117, China
  • Linyi Cancer Hospital
    Linyi, Shandong 276002, China
  • Yantai Yuhuangding Hospital
    Yantai, Shandong 264099, China
  • Obstetrics & Gynecology Hospital of Fudan University
    Shanghai, Shanghai Municipality 200090, China
  • TianJin Medical University Cancer Institute & Hopspital
    Tianjin, Tianjin Municipality 300181, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2022 to primary completion in Feb 2024, 17 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 6, 2022
First posted
Aug 1, 2022
StartActual
Aug 26, 2022
Primary completionActual
Feb 1, 2024
CompletionActual
Nov 30, 2025
Last update
Jan 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05481645
Responsible party
Sponsor
First posted
Aug 1, 2022
Start date
Aug 26, 2022
Primary completion
Feb 1, 2024
Completion
Nov 30, 2025
Last update
Jan 9, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Catequentinib hydrochloride

Start the discussion